Evidence map›Paper›PMID 42629317›Full record

ArticleJournal of labelled compounds & radiopharmaceuticals2026

Reliable One-Pot Automated Preparation of [

Hiroki Hashimoto, Takayuki Ohkubo, Kaito Tsukagoe, Tomoya Fujishiro, Daisuke Arashi, Tatsuto Sato, Takeru Seki, Yusuke Kurihara, Masanao Ogawa, Masatoshi Muto and 5 more

Abstract read
In one paragraph

Article in Journal of labelled compounds & radiopharmaceuticals, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Hiroki HashimotoDepartment of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), Chiba, Japan.
Takayuki OhkuboDepartment of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), Chiba, Japan.
Kaito TsukagoeDepartment of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), Chiba, Japan.
Tomoya FujishiroDepartment of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), Chiba, Japan.
Daisuke ArashiDepartment of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), Chiba, Japan.
Tatsuto SatoDepartment of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), Chiba, Japan.
Takeru SekiDepartment of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), Chiba, Japan.
Yusuke KuriharaDepartment of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), Chiba, Japan.
Masanao OgawaDepartment of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), Chiba, Japan.
Masatoshi MutoDepartment of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), Chiba, Japan.
Nobuki NengakiDepartment of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), Chiba, Japan.
Wakana MoriDepartment of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), Chiba, Japan.
Masayuki FujinagaDepartment of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), Chiba, Japan.
Kazunori KawamuraDepartment of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), Chiba, Japan.ORCID https://orcid.org/0000-0001-6786-678X
Ming-Rong ZhangDepartment of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), Chiba, Japan.ORCID https://orcid.org/0000-0002-3001-9605

Funding

Japan Agency for Medical Research and Development (AMED) 24zf0127012Japanese Ministry of Education and Japan Society for the Promotion of Science, Culture, Sports, Science, and Technology 23H02867Japanese Ministry of Education and Japan Society for the Promotion of Science, Culture, Sports, Science, and Technology 24K21295
6 · The paper itself

Abstract

We clinically investigated (S)-5-methoxymethyl-3-[6-(4,4,4-trifluorobutoxy)benzo[d]isoxazol-3-yl]oxazolidin-2-[

Indexed as

Carbon RadioisotopesIsoxazolesRadiochemistryRadiopharmaceuticalsAutomationChemistry Techniques, SyntheticIsotope LabelingPositron-Emission TomographyCarbon-11Carbon RadioisotopesIsoxazolesRadiopharmaceuticalscarbon‐11CO2 fixationquality controlradiosynthesisSL25.1188

Identifiers

PMID42629317
PMCPMC13498465

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.